Improving the Diagnosis and Management of Pulmonary Progressive Fibrosis (PPF): A Focus on Systemic Sclerosis Interstitial Lung Disease (SSc-ILD) and Idiopathic Pulmonary Fibrosis (IPF)
Released On
October 25, 2024
Expires On
September 2, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Pulmonology, Rheumatology
Topics
Pulmonary Fibrosis
Provided by The France Foundation.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses - 1.0 Nursing Contact Hours
- Physician Associate — 1.0 AAPA Category 1 CME credits
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of rheumatologists, pulmonologists, and advanced practice providers.
Program Overview
This activity features an interactive case-based format where you can review questions to determine best practices in diagnosing and managing PPF, SSc-ILD, and IPF. This session offers real-life examples to help differentiate diseases within the Pulmonary Progressive Fibrosis (PPF) group, such as Idiopathic Pulmonary Fibrosis (IPF) and Systemic Sclerosis Interstitial Lung Disease (SSc-ILD), by focusing on pathophysiology, prevalence, and disease burden.
Participants will learn best practices for diagnosis and routine assessment, while staying updated on ongoing clinical research and treatment guidelines impacting the multidisciplinary management of these diseases.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Differentiate certain diseases within the progressive pulmonary fibrosis (PPF) grouping, such as systemic sclerosis interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF), in terms of their pathophysiology, prevalence, and burden of disease
- Identify best practices in the diagnosis and routine assessment of patients with PPF, IPF, and SSc-ILD, in accordance with current guidelines, via real-world patient case scenarios
- Recognize ongoing developments in clinical research and treatment guidelines that may impact the multidisciplinary management of these diseases going forward
Faculty
Elizabeth R. Volkmann, MD, MS
Associate Professor
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA
Scott Matson, MD
Assistant Professor
Division of Pulmonary, Critical Care, and Sleep Medicine
The University of Kansas Medical Center
Kansas City, KS
Accreditation Statement
In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation
Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.Physicians should only claim the credit commensurate with the extent of their participation in the enduring activity.
Nurses
The France Foundation designates this activity for 1.0 contact hours.
Physician Associates
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until September 02, 2025. PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflicts Of Interest
- Elizabeth Volkmann, MD, MS
- Non-CE Consulting relationships with Boehringer Ingelheim and GlaxoSmithKline
- Non-CE Speakers’ Bureau relationship with Boehringer Ingelheim
- Contract Research relationships with Boehringer Ingelheim, Forbius, Horizon, Kadmon Corporation, and Prometheus Biosciences
- The financial relationship with Boehringer Ingelheim for Non-CE Speakers Bureau was mitigated by ending in December 2022
- All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee member
- Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
- Non-CE Consulting relationships with Boehringer Ingelheim and GlaxoSmithKline
- Scott Matson, MD
- Dr. Matson has no relevant financial information to disclose
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures
- Participate in the online activity
- Submit the evaluation form
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The France Foundation (TFF) requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
For CME questions please contact The France Foundation at 860-434-1650 or [email protected].